Management of Extremity Venous Thrombosis in Neonates and Infants: An Experience From a Resource Challenged Setting

Ahmed Mousa, MD, FRCS, FACS1,2,3, Ossama M. Zakaria, MD2,3, Ibrahim Hanbal, MD1, Mohammed A. Nasr, MD4, Tamer A. Sultan, MD5, Mohamed Abd El-Hamid, MD1, Amr M. El-Gibaly, MD6, Haytham Al-Arfaj, SB2, Ahmed S. Daha, MD1, Mohammed A. Buhalim, SB2, Mohamed Y. Zakaria, MD1, Dina E. El Metwally, MD7, Bosat E. Bosat, MD8, Alaa Sharabi, MD1, Mohamed Nienaa, MD2, Mahsoub M. Amin, MD1, and Khaled A. Rashed, MD9

Abstract
We aimed to evaluate the outcome of different treatment modalities for extremity venous thrombosis (VT) in neonates and infants, highlighting the current debate on their best tool of management. This retrospective study took place over a 9-year period from January 2009 to December 2017. All treated patients were referred to the vascular and pediatric surgery departments from the neonatal intensive care unit. All patients underwent a thorough history-taking as well as general clinical and local examination of the affected limb. Patients were divided into 2 groups: group I included those who underwent a conservative treated with the sole administration of unfractionated heparin (UFH), whereas group II included those who were treated with UFH plus warfarin. Sixty-three patients were included in this study. They were 36 males and 27 females. Their age ranged from 3 to 302 days. Forty-one (65%) patients had VT in the upper limb, whereas the remaining 22 (35%) had lower extremity VT. The success rate of the nonsurgical treatment was accomplished in 81% of patients. The remaining 19% underwent limb severing, due to established gangrene. The Kaplan-Meier survival method revealed a highly significant increase in both mean and median survival times in those groups treated with heparin and warfarin compared to heparin-only group (P < .001). Nonoperative treatment with anticoagulation or observation (ie, wait-and-see policy) alone may be an easily applicable, effective, and a safe modality for management of VT in neonates and infants, especially in developing countries with poor or highly challenged resource settings.

Keywords
anticoagulants, thrombosis, venous thromboembolism, heparins, pediatric thrombosis

Date received: 19 July 2018; revised: 24 September 2018; accepted: 15 October 2018.

1 Department of Vascular Surgery, Al-Hussain University Hospital, Faculty of Medicine for Males, Al-Azhar University, Cairo, Egypt
2 Divisions of Vascular Surgery, Pediatric Surgery, General Surgery, Emergency Medicine; Department of Surgery, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
3 Division of Pediatric Surgery, Department of Surgery, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
4 Division of Vascular Surgery, Department of Surgery, Faculty of Medicine, Al-Azhar University, Assiut Branch, Assiut, Egypt
5 Division of Pediatric Surgery, Department of Surgery, Faculty of Medicine, Menoufia University, Menoufia, Egypt
6 Department of General, Visceral, Thoracic and Vascular Surgery, Hanse Klinikum Stralsund, University Medicine of Greifswald, Stralsund, Germany
7 Department of Pediatrics, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
8 Department of General Surgery, Al-Zahraa University Hospital, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
9 Department of Pediatrics, Al-Hussain University Hospital, Faculty of Medicine for Male, Al-Azhar University, Cairo, Egypt

Corresponding Author:
Ahmed Mousa, MD, FRCS, FACS, Department of Vascular Surgery, Al-Hussain University Hospital, Faculty of Medicine for Males, Al-Azhar University, Cairo, Egypt; Division of Vascular Surgery, Department of Surgery, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia. Emails: isvascular@yahoo.com; asgbi@azhar.edu.eg
Introduction

Neonatal and infantile venous thrombosis (VT) although being rare has dramatically increased during the last decade by over 70%.[1] This pathology poses a major challenge to neonatologists, pediatricians, and surgeons with an increased morbidity, mortality and health-care costs.[2] The increased incidence may be attributed to the more aggressive care of neonates and infants with serious and life-threatening disorders.[1,2] Prolonged use of intravenous (IV) catheters may be indicated by the occurrence of superficial thrombophlebitis and, less often, deep VT (DVT). Various indirect factors such as prolonged sepsis, trauma, and congenital heart diseases may trigger spontaneous thrombosis in the pediatric population.[3,4] In critically ill neonates and infants, central venous catheters (CVCs) are commonly used for parenteral nutrition/giving medication. These catheters are usually inserted in central or peripheral veins. However, the most frequently encountered complications associated with CVC insertion is the development of VT. The incidence of CVC-related thrombosis in neonates and infants depends on the type of the catheter used, the used diagnostic tests, and the index of suspicion for development of thrombosis.[5,6] Development of spontaneous/catheter-related VT may be associated with prothrombotic genetic factors compared to the general population.[7,8] Consequently, venous thromboembolism (VTE), despite being rare, may lead to gangrene of the extremities in those neonates and infants. Conservative management of this pathology is the best option for treating most of the cases with an ongoing debate regarding which treatment modality is the best.[9,10] The aim of this work was to evaluate the outcome of different treatment modalities for treatment of post-injection/infusion peripheral venous gangrene in neonates and infants, highlighting the current debate.

Methods

This 9-year retrospective study was performed from January 2009 until December 2017, after being approved by our institutes’ researcher board ethical committees. Infants and neonates were considered for enrollment if they were referred from the neonatal intensive care unit for having manifestations of upper or lower extremity threatening gangrene post-IV injection/infusion. Those patients’ files were thoroughly reviewed. Patients were classified into 2 groups; the first group (GI) included those who underwent the administration of unfractionated heparin (UFH) alone, whereas the second group (GII) included those who had the same regimen of UFH, plus the addition of warfarin (vitamin K antagonists). Clinically, neonates and infants were considered having extremity VT and consequently gangrene if they were presented with an extremity swelling, limb pain, cyanotic/hyperemic/tenderness of the affected arm or leg, or with a fixed color change. Also considered as VT, were the presence of subcutaneous collateral veins, (provided that there is a history of either IV injection/infusion of the affected limb), CVC dysfunction, as well as unexplained thrombocytopenia, hemodynamic disturbance, and arrhythmias.[12-14] Excluded from this study were those patients with arterial thrombosis, cerebral sinus VT, renal vein thrombosis, hemolytic disorders, and those with preexisting/known prothrombotic risk factors (diagnosed by laboratory tests). Diagnostic imaging modalities included color Doppler ultrasonography, contrast venography, and computerized tomography scanning/magnetic resonance venography as described in the literature.[15] Furthermore, local treatment to the affected limb was adopted by removal of the IV line, cold fomentations, local antiseptic, and limb elevation. Systemic antibiotics after gaining blood culture were carried out. Following exclusion of intraventricular bleeding, patients are allocated to systemic anticoagulation therapy. Additionally, pretreatment laboratory testing was conducted, including complete blood count, type and screen, prothrombin time as well as the international normalized ratio (INR), alanine aminotransferase, aspartate aminotransferase, bilirubin total and direct as well as creatinine levels. As previously described,[16,17] all patients were conservatively treated with anticoagulants, namely UFH with a dosage of 75 to 100 units/kg over 10 minutes duration. Moreover and according to the recommendations of the American College of Clinical Pharmacy guidelines for heparin administration with prior warfarin intake, the required time to reach a therapeutic level ranged between 3 to 5 days due to the procoagulant transient effect.[16,18-20] It was avoided in those children who had a significant risk of bleeding. According to the CHEST guidelines, the initial infusion stated with a dosage of 28 units/kg per hour, with infants (aged 2 months up to <1 year corrected for gestational age); yet, we considered the individual risk factors when choosing initial dose.[21,22] The adjustment of heparin maintenance dose was determined to maintain aPTT between 55 and 85 seconds. It was usually assessed within 4 to 6 hours of the loading heparin dosage and 4 hours post any change in the infusion rate. It was measured daily once the needed therapeutic levels were achieved.[22] Furthermore, we adopted the use of an initial warfarin dosage of 0.33 mg/kg aiming to reach a therapeutic INR level of 2.5 (ranging 2.0-3.0), according to the infantile INR nomogram[23,24] (Table 1). Heparin-induced major bleeding was treated by the transient termination of IV heparin infusion, in addition to the immediate administration of protamine sulfate and blood transfusion. The dose of protamine sulfate was determined according to the previously 2 hours of heparin administration.[21]

Table 1. Dose of Anticoagulants.

| Factor                  | GI Heparin Only (n = 46) | GI Heparin + Warfarin (n = 17) |
|-------------------------|--------------------------|-------------------------------|
| Anticoagulant Initial dose | 75-100 U/kg               | 75-100 U/kg + 0.33mg/kg       |
| Maintenance             | 28 U/kg/h                 | 28 U/kg/h + 0.33mg/kg         |
**Statistical Analysis**

Data were statistically analyzed using the Statistical Package for the Social Science (SPSS) version 23, IBM Corporation, Armonk, New York. Continuously distributed variables were summarized by the mean and standard deviation (SD) or median and range. In addition, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Finally, the Kaplan-Meier survival analysis was used to graphically describe amputation-free survival and a *P*-value of < .05 was statistically significant.

**Results**

Sixty-three patients were included in this study. They were 36 males and 27 females with the male to female ratio of 1.3:1. Their age ranged from 3 up to 302 days with a mean of (72.10 ± 61.60). Most patients were premature (79% (n = 50), with a gestational age range from 32 to 34 weeks (mean = 33 ± 8; Table 2). Forty-one (65%) patients had VT in the upper limb (Figure 1), whereas the remaining 22 (35%) had lower limb VT (Figure 2). Out of those 41 patients with upper limb VT, 4 (6.5%) patients had only 1 finger gangrene. Three (5%) patients had gangrene affecting more than 1 finger, and 1 patient (1.5%) had gangrene of the whole hand. On the other hand, 4 (6%) patients with lower limb VT developed gangrene in 1 toe 3% (n = 2), multiple toes in 1.5% (n = 1), and whole foot gangrene in 1.5% (n = 1; Table 2). Seventeen (77.3%) patients underwent central venous catheterization inserted into the femoral vein whereas the remaining 5 (22.7%) patients had a peripheral venous catheter. The overall success rate of the nonsurgical treatment adopted on all patients was 81% (n = 51). The remaining 19% (n = 12) patients underwent amputation due to an established gangrene. However, in GI, 46 patients who underwent treatment with UFH alone, 35 of them showed the success of the treatment, whereas in the remaining 11 patients the treatment was not successful necessitating finger, toe, or even limb amputation in. Alternatively, in GII, 16 patients showed a successful response to the combination of UFH and warfarin therapy with only 1 patient who underwent little toe amputation due to the failure of treatment (Table 3 and Figure 3). The average time of conservative treatment showed a range of 7 to 22 days (mean = 15.1 ± 1.6). The total mortality rate was 3 (5%) out of the total 63 patients. Postoperatively, 2 patients died due to severe sepsis whereas the remaining one expired before surgery due to severe complicated multiple congenital anomalies.

Major bleeding events because of UFH administration were encountered among 2 (3%) patients in GI and in 1 (1.5%) patient in GII. Yet, warfarin-induced major bleeding was not
Many factors may have contributed to the increased incidence of VT and consequently gangrene. The highest risk of developing VT and consequently gangrene is observed in patients with systemic inflammation, sepsis, liver dysfunction, peripheral and central venous lines, fluid fluctuations, and systemic inflammation. Central venous catheter is one of the most common clinical factors that may be responsible for the development of VT and gangrene. Due to both increased plasma levels of plasminogen activator inhibitor and decreased plasma activity of plasminogen, the activity of the fibrinolytic system in the newborn is reduced compared to adults and older children. This fact may explain the high rate of VT associated with the insertion of intravascular devices in the newborns.

Treatment of a newborn with VT is usually difficult with the use of antithrombotic therapy. This may be due to the altered physiology and metabolism of the anticoagulants. The current study reported 4 (6.5%) cases who underwent VT and consequently gangrene of the lower limb induced by CVCs. These data are contradicting with a 30% incidence of CVC-associated VT in a previously published report. Moreover, venous thromboses are more likely pronounced in premature infants. We also reported VT in 38.1% premature infants. This is comparable to other literature data, whereas preterm neonates accounted for 34% of the thrombos.

Most of our patients were in the neonatal period (n = 55) 87%, coinciding with previously published reports that showed an incidence of neonatal thrombosis to be 2.4/1000 and 5.1/100.000, respectively. It may be due to a higher hematocrit as well as the greater liability of the hemostatic system because of a general decrease in levels of coagulation factors and their inhibitors in neonates. Neonatal extremity VT and consequently gangrene is usually treated conservatively aiming to prevent the occurrence of infection at the affected part, allowing the gangrenous area to declare spontaneously in order to optimize any future reconstruction.

The anticoagulant most commonly used in the treatment of neonatal VTE is UFH, although LMWH can also be used. The advantages of UFH include the potentially easier reversibility with protamine sulfate. However, bleeding complication is the main risk-associated with heparin administration. The incidence of bleeding complication following anticoagulant administration in our series was reported in 3% and 1.5% in GI and GII, respectively. These results coincide and nearly similar to the previously published reports of 2% incidence of major bleeding using UFH, although it contradicts to other literature data reporting an incidence that reached 24%.

The recommendations for treatment of adult VTE cannot apply to the management of neonatal and infantile VTE, as their vascular system, the hemostatic system, and comorbidities create a balance of hemorrhage and thrombosis. The severity of the thrombosis, the possibility of limb impairment, the presence of comorbidities, and the risk of bleeding all influence the decision to treat or to observe. Randomized trials evaluating type and duration of treatment are lacking in the neonatal population, and treatment decisions are largely based on consensus evidence-based guidelines. The anticoagulant therapy reduces the risk of thrombus extension and subsequently pulmonary embolism, while allowing the natural fibrinolytic system to gradually reduce the clot size. Although controversy exists in the literature, as regard the best tool for conservatively treating VT and consequently gangrene, we reported 51 (81%) patients out of 63 patients with a good response to UFH despite not using LMWH because of the financial limitations in our settings. Nevertheless, previously published data from highly developed settings expressing both the Canadian and German experience suggested the use of thrombolysis and anticoagulation in the form of UFH and LMWH as the primary tool for treating this condition. Yet, it is difficult to verify which treatment modality is superior to the other.
In those 2 registries, the most frequently used drug was heparin as the anticoagulant of choice. Other Canadian research did use the LMWH and found out that it might have the advantages over the standard UFH. This may explain that neonates and infants might require LMWH as well as UFH.\textsuperscript{36,37} Furthermore, monitoring of the therapeutic effect of LMWH requires the determination of anti-Xa, which is practically unfeasible in our settings.

**Conclusion**

Catheter-related VT—whether centrally or peripherally located—was frequently encountered in our series, despite their little number in the literature. This may be due to the presence of infection/inadequate nursing care owing to lack of training in proper insertion and hygienic care of the venous catheters in neonates and infants. Therefore, it is strongly recommended to adopt more aggressive programs on teaching nurses and paramedics indulged in the neonatal care on how to properly insert and hygienically care of venous catheters. Additionally, we highly advocate the initial aggressive therapy using heparin with early bridging with warfarin. This regimen is feasible, reliable, effective, and may be safe modality for management of neonatal and infantile extremity VT having good outcome results with a lower incidence of amputation, especially in developing countries with poor or highly limited-resource settings. The study is limited by the variability of vascular care policies and procedures among the different institutions in the study. Another issue is the lack of information on infants and children hospital course, and on associated diagnosis of familial or genetic thrombotic disease. These limitations may be solved by adopting a future prospective research on the topic.

**Authors’ Note**

AM, OMZ, IH, MAN, TAS, MA, AME, HA, ASD, MAB, MYZ, DEE, BEB, ASH, MN, MMA, KAR made a substantial contribution to the acquisition of the work. AM, OMZ, IH, MAN, TAS, MA, AME, HA, ASD, MAB, MYZ, DEE, BEB, ASH, MN, MMA, KAR performed the analysis and interpretation of data. AM, OMZ, IH, MAN, TAS, MA, AME, HA, ASD, MAB, MYZ, DEE, BEB, ASH, MN, MMA, KAR performed the acquisition of data. AM, OMZ, IH, MAN, TAS, MA, AME, HA, ASD, MAB, MYZ, DEE, BEB, ASH, MN, MMA, KAR revised it critically for important intellectual content AM, OMZ, IH, MAN, TAS, MA, AME, HA, ASD, MAB, MYZ, DEE, BEB, ASH, MN, MMA, KAR final approval of the version to be published. All authors read and revised the manuscript carefully for final publication in response to the reviewers’ comment. All procedures performed in study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or

**Table 4.** Cross Tabulation Between Treatment and Amputation in the Studied Groups.

| Treatment               | Heparin   | Count | % within treatment (AR) | Heparin + warfarin | Count | % within treatment (AR) | Total | Count | % within treatment (AR) |
|-------------------------|-----------|-------|-------------------------|-------------------|-------|-------------------------|-------|-------|-------------------------|
|                         |           |       |                         |                   |       |                         |       |       |                         |
| No amputation           |           |       |                         |                   |       |                         |       |       |                         |
| Heparin                 | 35        |       | 76.1%                   | 16                |       | 94.1%                   | 51    | 81%   | 19%                     |
| Amputation              | 11        |       | 23.9%                   | 1                 |       | 5.9%                    | 12    | 19%   | 100%                    |
| Total                   | 46        |       | 100%                    | 17                |       | 100%                    | 63    | 100%  |                         |

Pearson $\chi^2 = 2.617, P = .106$

Odds ratio (heparin/heparin + warfarin) = 0.199; CI = 0.024-1.67

Odds ratio (heparin + warfarin/heparin) = 4.065; CI = 0.56-29.15

**Table 5.** Mean and Median Survival Times in the Studied Groups

| Group                    | Mean Estimate | SE | Median Estimate | SE |
|--------------------------|---------------|----|-----------------|----|
| Heparin only (group I)   | 8.000         | 0.382 | 8.000          | 0.672 |
| Heparin and warfarin (group II) | 31.938       | 9.561 | 10.000         | 2.000 |

$\chi^2 = 10.421, df = 1, P < .001$

**Abbreviations:** AR, absolute risk; CI, confidence interval.

**Figure 4.** Survival curve for the 2 studied groups using the Kaplan-Meier method.
comparable ethical standards. As this is a retrospective study, an informed consent in this article was not obtained.

Acknowledgments
The authors would like to thank Prof. Tarek D. Hussein, Professor of Zoology, Faculty of Science, Cairo University; for his effort for performing the statistical analysis for this article.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Ahmed Mousa, MD, FRCS, FACS https://orcid.org/0000-0002-0840-4080

References
1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009;124(4):1001-1008.
2. Jaffraya J, Mahajerin A, Young G, et al. A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children’s Hospital-Acquired Thrombosis (CHAT) project. Thromb Res. 2018;161:67-72.
3. Cohn AT, Tapson VF, Bergmann JF, et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
4. Sani UM, Oboirien M, Waziri UM, Issezoo KO, Garba BI, Oyibo E. Left lower Limb Gangrene Following Diarrhoeal Disease and Dehydration in a child with Transposition of the Great Arteries. E. Left lower Limb Gangrene Following Diarrhoeal Disease and Dehydration in a child with Transposition of the Great Arteries. Ann Med Health Sci Res. 2017;7(2):69-72.
5. Umar LW, Ya’uba MS, Olorukooba AA, Abubakar Y, Mohammed AJ, Chom ND. Purpura fulminans with disseminated intravascular coagulopathy and symmetric peripheral gangrene complicating sepsis in an infant: a case report. Ann Med Health Sci Res. 2017;7(2):69-72.
6. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost. 2001;86(1):464-474.
7. Park CK, Paes BA, Nagel K, Chan AK, Murthy P. Neonatal central venous catheter thrombosis: diagnosis, management and outcome. Blood Coagul Fibrinolysis. 2014;25(2):97-106.
8. Nowak-Gottl U, Dubbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr. 1997;131(4):608-612.
9. Fijnheer R, Pajimans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol. 2002;118(1):267-270.
10. Chalmers EA. Neonatal thrombosis. J Clin Pathol. 2000;53(6):419-423.
11. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139(5):676-681.
12. Veldman A, Nold MF, Michel-Behnke I. Thrombosis in the critically ill neonates: incidence, diagnosis, and management. Vasc Health Risk Manag. 2008;4(6):1337-1348.
13. Nowak-Gottl U, von Kries R, Golub U. Neonatal symptomatic thromboembolism in children: two year survey. Arch Dis Child Fetal Neonatal Ed. 1997;76(3):F163-F167.
14. Will A. Neonatal haemostasis and the management of neonatal thrombosis. Br J Haematol. 2015;169(3):324-32.
15. Male C, Kuhle S, Mitchell L. Diagnosis of venous thromboembolism in children. Semin Thromb Hemost. 2003;29(4):377-390.
16. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35(1):78-83.
17. Haley KM. Neonatal Venous Thromboembolism. Front Pediatr. 2017;5(6):136.
18. Heptonstall M, Chan A, Monagle P. Antiocoagulation therapy in neonates, children and adolescents. Blood Cells Mol dis. 2017;67:41-47.
19. Haroon Y, Shearer MJ, Rahim S, Gunn WG, McEnery G, Barkhan P. The content of phyloquinone (vitamin K1) in human milk, cows' milk and infant formula foods determined by high-performance liquid chromatography. J Nutr. 1982;112(6):1105-1117.
20. von Kries R, Shearer M, McCarthy PT, Haug M, Harzer G, Golub U. Vitamin K1 content of maternal milk: influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr Res. 1987;22(5):513-517.
21. Monagle P, Chan AK, Goldberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(suppl 2):e737S-e801S.
22. Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost. 2010;104(4):837-844.
23. Kuhle S, Eulemessekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinical significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica. 2007;92(2):244-247.
24. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. 1993;119(9):874-881.
25. Jones DR, Macintyre IM. Venous thromboembolism in infancy and childhood. Arch Dis Child. 1975;50(2):153-155.
26. Amankwah EK, Atchison CM, Arlikar S, et al. Risk factors for hospital-associated venous thromboembolism in the neonatal intensive care unit. Thromb Res. 2014;134(2):305-309.
27. Klaassen IL, van Ommen CH, Middeldorp S. Manifestations and clinical impact of pediatric inherited thrombophilia. Blood. 2015; 125(7):1073-1077.

28. Chalmers EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res. 2006;118(1):3-12.

29. Tanke RB, van Megen R, Daniels O. Thrombus detection on central venous catheters in the neonatal intensive care unit. Angiology. 1994;45(6):477-480.

30. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 1995;96(5 pt 1):939-943.

31. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362-372.

32. Prasad R, Kumar V, Mishra OP, Verma A. Left Common Femoral Vein Thrombosis with Lower Limb Gangrene in a Newborn. J Pediatr Neonatal Care. 2016;5(8):00218.

33. Ozgenel GY, Akin S, Uysal A, Koksal N. Gangrene of the upper extremity in the newborn. Eur J Plast Surg. 2000;23:429-431.

34. Puymirat E, Aissaoui N, Silvain J, et al. Comparison of bleeding complications and 3-year survival with low-molecular weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry. Arch Cardiovasc Dis. 2012;105(5-6):347-354.

35. Greenway A, Massicotte MP, Monagle P. Neonatal thrombosis and its treatment. Blood Rev. 2004;18(2):75-84.

36. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128(3):313-318.

37. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 1998;132(4):575-588.